Atrial fibrillation (anterior fibrillation) is a heart rhythm disorder characterized by an irregular heart rhythm and usually associated with diseases such as heart failure, coronary disease, heart valve disease, diabetes and high blood pressure. Paroxysmal atrial fibrillation is characterized by returning to a normal sinus rhythm, a persistent atrial fibrillation is chronically irregular heart rhythm, without returning to the sinus rhythm.


  • Ischemic heart disease, valvular disease, infection (pericarditis and myocarditis)
  • Age, alcohol consumption, respiratory, endocrine and nervous system diseases


In most patients, asymptomatic

Symptoms commonly present are: palpitations or premature heartbeat, choking, difficulty breathing, rapid fatigue, dizziness and unconsciousness, feelings of tightness in the chest.


  • Anamnesis, complete physical examination with blood pressure and ECG, as well as laboratory analysis
  • An examination may be supplemented by heart echocardiography, rhythm holter, and physical load test


  • Medicines (antiarrhythmics), with a treatment of associated diseases (a treatment and dosage of medicines is determined for each patient individually)
  • Anti-coagulation medicines (anticoagulant medicines) are an integral part of the treatment of atrial fibrillation. The goal of anticoagulant therapy is to prevent thromboembolic complications. These medicines should be taken exactly as prescribed and their effect is regularly monitored by appropriate laboratory blood tests (INR, PT)
  • Non-pharmacological methods of treatment: electroconversion, electrostimulator implantation (pacemaker and defibrillator), radiofrequency ablation and surgical treatment

Atrial fibrillation prognosis

  • Patients with atrial fibrillation have a higher risk of potentially severe complications, to a large extent thromboembolic events
  • The onset of atrial fibrillation usually indicates the initial phase of heart failure.

About Heart Center BH

Copyright by Medical Institute Bayer, 2020. All rights reserved.

Poštovani posjetioci, ovom prilikom Vas želimo obavijestiti da od januara 2020. godine "Centar  za srce BH" Tuzla nastavlja da posluje u sklopu zdravstvene
ustanove Specijalna bolnica "Medical Institute Bayer".